HAITILS-PHP: Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases

Sponsor

Vastra Gotaland Region (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT05903937

Collaborator

(none)

Enrollment

Arm

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

Evaluate the safety and tolerability of treatment with autologous tumor infiltrating lymphocytes (TIL) administered via hepatic arterial infusion and preconditioning with percutaneous hepatic perfusion in patients with liver metastases (but not restricted to) of malignant melanoma

Condition or Disease	Intervention/Treatment	Phase
Uveal Melanoma Metastatic Cutaneous Melanoma	Drug: Autologous Tumor Infiltrating Lymphocytes Drug: Melphalan Drug: Interleukin-2	Phase 1

Study Design

Study Type:

Interventional

Anticipated Enrollment :

6 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes Preconditioned With Percutaneous Hepatic Perfusion With Melphalan in Patients With Melanoma and Liver Metastases

Anticipated Study Start Date :

Dec 31, 2023

Anticipated Primary Completion Date :

Dec 31, 2024

Anticipated Study Completion Date :

Dec 31, 2029

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Autologous tumor infiltrating lymphocytes (TIL)	Drug: Autologous Tumor Infiltrating Lymphocytes Administered via hepatic arterial infusion (HAI) Drug: Melphalan Administered via isolated hepatic perfusion Drug: Interleukin-2 low-dose, administered s.c.

Arm

Intervention/Treatment

Experimental: Autologous tumor infiltrating lymphocytes (TIL)

Drug: Autologous Tumor Infiltrating Lymphocytes

Administered via hepatic arterial infusion (HAI)

Drug: Melphalan

Administered via isolated hepatic perfusion

Drug: Interleukin-2

low-dose, administered s.c.

Outcome Measures

Primary Outcome Measures

Incidence and severity of adverse events [5 years]
Graded according to Common Terminology Criteria for Adverse Events version 5.0

Secondary Outcome Measures

Objective response rate [5 years]
Defined as the proportion of patients with a best overall response of partial response or better defined by RECIST 1.1
Progression-free survival [5 years]
Defined as the time from inclusion to objective tumor progression (determined by RECIST 1.1), or death due to any cause, whichever occurred first.
hepatic Progression-free survival [5 years]
Defined as the time from inclusion to objective tumor progression in the liver (determined by RECIST 1.1), or death due to any cause, whichever occurred first.
Duration of response [5 years]
Defined as the time from the first documented response and the date of the first documented tumor progression, death, or the last tumor assessment that occurred before subsequent therapy.
Overall survival [5 years]
Defined as the time from inclusion to the date of death due to any cause
Evaluation of Tolerability [5 years]
Defined as the proportion of patients included that receive PHP and TIL

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patient is willing and able to provide written informed consent and comply with study procedures. Written informed consent must be signed and dated before the start of specific protocol procedures.
Patient must have a histologically/cytologically confirmed diagnosis of:
stage IV uveal melanoma with or without any previous systemic therapy OR
stage IV cutaneous melanoma with confirmed progression following at least one or two prior systemic therapies including a programmed cell death protein-1 (PD-1) inhibitor with or without a CTLA-4 inhibitor; and if BRAF V600 mutation-positive, also a BRAF inhibitor or a BRAF inhibitor in combination with a MEK inhibitor.
Measurable disease by computed tomography (CT) per RECIST 1.1 criteria with at least one target lesion identified in the liver and where the distribution pattern of metastasis is predominantly engaging the liver as judged by the investigator.
At least one resectable lesion in the liver (or aggregate of lesions resected) of a minimum size of 0.5 cm in diameter post- resection to generate TILs.
ECOG performance status of 0 - 1.

Exclusion Criteria:

Life expectancy of less than 3 months.
Reduced renal function defined as S-Creatinine >=1.5xULN or Creatinine Clearance < 40 mL/min, calculated using the Cockroft and Gault formula.
Reduced hepatic function (defined as ASAT, ALAT, bilirubin > 3*ULN and PK- INR > 1.5) or medical history of liver cirrhosis or portal hypertension.
Hemoglobin <90 g/L or platelets <100x109/L or neutrophils <1.5x109/L
Use of live vaccines four weeks before or after the start of study.
Infection of human immunodeficiency virus (HIV), acquired immunodeficiency syndrome (AIDS), hepatitis B or hepatitis C.
Active autoimmune disease.
A condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses >10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
Concomitant therapy with any other anti- cancer therapy, concurrent medical conditions requiring use of immunosuppressive medications or use of other investigational drugs.
Has a known additional malignancy of other diagnosis that is progressing or requires active treatment.
A history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator